Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report

Por Casadei Gardini, Andrea, Chiadini, Elisa, Faloppi, Luca, Marisi, Giorgia, Delmonte, Angelo, Scartozzi, Mario, Loretelli, Cristian, Lucchesi, Alessandro, Oboldi, Devil, Dubini, Alessandra, Frassineti, Giovanni Luca, Ulivi, Paola
Publicado no BMC Cancer (2016)

Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?

Por Ulivi, Paola, Delmonte, Angelo, Chiadini, Elisa, Calistri, Daniele, Papi, Maximilian, Mariotti, Marita, Verlicchi, Alberto, Ragazzini, Angela, Capelli, Laura, Gamboni, Alessandro, Puccetti, Maurizio, Dubini, Alessandra, Burgio, Marco Angelo, Casanova, Claudia, Crinò, Lucio, Amadori, Dino, Dazzi, Claudio
Publicado no Int J Mol Sci (2014)

Phase Ib of Sorafenib in Combination With Everolimus in Patients With Advanced Solid Tumors, Selected on the Basis of Molecular Targets

Por Toffalorio, Francesca, Spitaleri, Gianluca, Catania, Chiara, Dal Zotto, Laura, Noberasco, Cristina, Delmonte, Angelo, Santarpia, Mariacarmela, Vecchio, Fabio, Brunelli, Veronica, Rampinelli, Cristiano, Barberis, Massimo, Fumagalli, Caterina, Zucchetti, Massimo, Zangarini, Monique, Diena, Tullia, Danesi, Romano, de Braud, Filippo, De Pas, Tommaso
Publicado em 2014